Table I.
Patient characteristics and cycle parameters for the whole group and for development and validation samples.
| All | Development sample a | Validation sample | |
|---|---|---|---|
| N | 1282 | 414 | 868 |
| Female age (years) | 38.6 ± 5.4 | 38.4 ± 5.4 | 38.6 ± 5.4 |
| BMI (kg/m2)b | 23.8 (95% CI 23.6–24.1) | 23.8 (95% CI 23.4–24.3) | 23.8 (95% CI 23.5–24.1) |
| AMH (ng/ml)b | 0.65 (95% CI 0.61–0.74) | 0.75 (95% CI 0.65–0.88) | 0.63 (95% CI 0.56–0.71) |
| Max FSH (mIU/ml)b | 10.7 (95% CI 10.4–11.1) | 10.6 (95% CI 9.9–11.1) | 10.8 (95% CI 10.4–11.3) |
| Total gonadotrophins used (IU) | 5145 ± 2477 | 5419 ± 2510 | 5216 ± 2458 |
| Oocytes retrieved (n)b | 5.2 (95% CI 5.0–5.5) | 5.5 (95% CI 5.0–6.1) | 5.1 (95% CI 4.9–5.5) |
| High-quality embryos | 2.9 ± 3.5 | 2.9 ± 3.4 | 2.9 ± 3.6 |
| Pregnancy rate (%) | 20.6 (95% CI 18.4–22.8) | 21.0 (95% CI 17.1–25.0) | 20.4 (95% CI 17.7–23.1) |
| Live birth rate (%) | 15.8 (95% CI 13.8–17.8) | 16.4 (95% CI 12.8–20.0) | 15.6 (95% CI 13.1–18.0) |
Data are mean ± SD.
a
No characteristics were significantly different between the Development sample and the Validation sample.
b
Backtransformed after logarithmic transformation.
AMH, anti-Müllerian hormone.